About E3 ubiquitin-protein ligase TRIM11
E3 ubiquitin-protein ligase TRIM11 (TRIM11) is a protein
from Homo sapiens identified by UniProt accession
Q96F44, 468 residues long.
MolForge cross-references it against 0 known binders and
72 disease associations.
Target properties
| Protein name | E3 ubiquitin-protein ligase TRIM11 |
| UniProt accession | Q96F44 |
| Gene | TRIM11 |
| Organism | Homo sapiens |
| Length | 468 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (72)
Diseases linked to this target (Open Targets).
- clear cell renal carcinoma · score 0.18
- hepatocellular carcinoma · score 0.09
- gonorrhea · score 0.09
- calf circumference measurement · score 0.08
- non-small cell lung carcinoma · score 0.08
- Chordoma · score 0.08
- osteosarcoma · score 0.07
- prostate cancer · score 0.07
- neoplasm · score 0.07
- Ehlers-Danlos syndrome, musculocontractural type · score 0.06
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q96F44-F1 | alphafold | PREDICTED | 88.57 | — |
Amino-acid sequence (468 residues)
MAAPDLSTNL QEEATCAICL DYFTDPVMTD CGHNFCRECI RRCWGQPEGP YACPECRELS PQRNLRPNRP LAKMAEMARR LHPPSPVPQG VCPAHREPLA AFCGDELRLL CAACERSGEH WAHRVRPLQD AAEDLKAKLE KSLEHLRKQM QDALLFQAQA DETCVLWQKM VESQRQNVLG EFERLRRLLA EEEQQLLQRL EEEELEVLPR LREGAAHLGQ QSAHLAELIA ELEGRCQLPA LGLLQDIKDA LRRVQDVKLQ PPEVVPMELR TVCRVPGLVE TLRRFRGDVT LDPDTANPEL ILSEDRRSVQ RGDLRQALPD SPERFDPGPC VLGQERFTSG RHYWEVEVGD RTSWALGVCR ENVNRKEKGE LSAGNGFWIL VFLGSYYNSS ERALAPLRDP PRRVGIFLDY EAGHLSFYSA TDGSLLFIFP EIPFSGTLRP LFSPLSSSPT PMTICRPKGG SGDTLAPQ
Explore E3 ubiquitin-protein ligase TRIM11 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets